These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26491753)

  • 1. Tenacious D. why beta cells are no match for the relentless persistence of type 2 diabetes.
    Curry A
    Diabetes Forecast; 2015; 68(5):38-41. PubMed ID: 26491753
    [No Abstract]   [Full Text] [Related]  

  • 2. Beta-Cell Function and Its Underlying Mechanism 2015.
    Li Y; Wang C; Omar B; Chen L
    J Diabetes Res; 2016; 2016():7638120. PubMed ID: 26783538
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of High-Density Lipoproteins in Cholesterol Homeostasis and Glycemic Control.
    Manandhar B; Cochran BJ; Rye KA
    J Am Heart Assoc; 2020 Jan; 9(1):e013531. PubMed ID: 31888429
    [No Abstract]   [Full Text] [Related]  

  • 4. Are We There Yet?
    Tsai A
    Diabetes Forecast; 2016; 69(1):52-7. PubMed ID: 26983288
    [No Abstract]   [Full Text] [Related]  

  • 5. Pancreatic β cells: Gatekeepers of type 2 diabetes.
    Park YJ; Woo M
    J Cell Biol; 2019 Apr; 218(4):1094-1095. PubMed ID: 30696700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.
    Derosa G; Cicero AF; Franzetti IG; Querci F; Carbone A; Ciccarelli L; D'Angelo A; Fogari E; Maffioli P
    Can J Physiol Pharmacol; 2013 Sep; 91(9):724-32. PubMed ID: 23984793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of combining rosiglitazone with either metformin or insulin on β-cell mass and function in an animal model of Type 2 diabetes characterized by reduced β-cell mass at birth.
    Holloway AC; Hettinga BP; Gerstein HC
    J Diabetes; 2011 Mar; 3(1):74-81. PubMed ID: 21040499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HOMA-beta in the UKPDS and ADOPT. Is the natural history of type 2 diabetes characterised by a progressive and inexorable loss of insulin secretory function? Maybe? Maybe not?
    Reaven GM
    Diab Vasc Dis Res; 2009 Apr; 6(2):133-8. PubMed ID: 20368203
    [No Abstract]   [Full Text] [Related]  

  • 9. Insulin Innovations.
    Curry A
    Diabetes Forecast; 2015; 68(4):38-43. PubMed ID: 26374923
    [No Abstract]   [Full Text] [Related]  

  • 10. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
    Abel T; Fehér J
    Orv Hetil; 2010 Jun; 151(25):1012-6. PubMed ID: 20519186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive insulin therapy in newly diagnosed type 2 diabetes.
    Retnakaran R; Drucker DJ
    Lancet; 2008 May; 371(9626):1725-6. PubMed ID: 18502278
    [No Abstract]   [Full Text] [Related]  

  • 12. Protection of pancreatic beta-cells: is it feasible?
    Bonora E
    Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
    Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
    Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type 2 Diabetes: Progress Made but Still a Long Road to Travel to Reduce Disease Burden.
    Terra SG; Vincent J
    Clin Pharmacol Ther; 2015 Aug; 98(2):108-11. PubMed ID: 26013760
    [No Abstract]   [Full Text] [Related]  

  • 15. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New therapeutic options: management strategies to optimize glycemic control.
    Sisam DA
    J Am Osteopath Assoc; 2011 Apr; 111(4):300; author reply 300. PubMed ID: 21562302
    [No Abstract]   [Full Text] [Related]  

  • 17. Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Diabet Med; 2012 Dec; 29(12):1515-23. PubMed ID: 22540883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
    Liu Y; Hong T
    Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin degludec--the impact of a new basal insulin on care in type 2 diabetes.
    Khunti K; Cos X; Rutten G
    Prim Care Diabetes; 2014 Jul; 8(2):119-25. PubMed ID: 24207030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting protein misfolding to protect pancreatic beta-cells in type 2 diabetes.
    Costes S
    Curr Opin Pharmacol; 2018 Dec; 43():104-110. PubMed ID: 30245473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.